Melatonin is an indole hormone produced mainly by the pineal gland. We have previously demonstrated that melatonin interferes with estrogen (E 2 ) signaling in MCF7 cells by impairing estrogen receptor (ER) pathways. Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E 2 -induced ER␣-mediated transcription in both estrogen response element-and AP1-containing promoters, whereas ER␤-mediated transactivation is not inhibited or even activated at certain promoters. We show that the sensitivity of MCF-7 cells to melatonin depends on the ER␣/ER␤ ratio, and ectopic expression of ER␤ results in MCF-7 cells becoming insensitive to this hormone. Melatonin acts as a calmodulin antagonist inducing conformational changes in the ER␣-calmodulin (CaM) complex, thus impairing the binding of E 2 ⅐ER␣⅐CaM complex to DNA and, therefore, preventing ER␣-dependent transcription. Moreover the mutant ER␣ (K302G,K303G), unable to bind calmodulin, becomes insensitive to melatonin. The effect of melatonin is specific since other related indoles neither interact with CaM nor inhibit ER␣-mediated transactivation. Interestingly, melatonin does not affect the binding of coactivators to ER␣, indicating that melatonin action is different from that of current therapeutic anti-estrogens used in breast cancer therapy. Thus, they target ER␣ at different levels, representing two independent ways to control ER␣ activity. It is, therefore, conceivably a synergistic pharmacological effect of melatonin and current anti-estrogen drugs.
Melatonin is an indole hormone that is the major secretory product of the pineal gland. The most clearly defined actions of melatonin have been demonstrated on the reproductive system of seasonally breeding animals and on circadian rhythms and sleep. A rapidly emerging avenue of investigation is the oncostatic and anti-proliferative effects of melatonin on endocrineresponsive neoplasms, especially in those concerning the mammary gland (1) . The most common conclusion in animal models of tumorigenesis is that either experimental manipulations that activate the pineal gland or the administration of melatonin reduces the incidence and development of chemically induced mammary tumors, whereas pinealectomy usually stimulates breast cancer growth (2) (3) (4) . Epidemiological studies have shown a low incidence of breast tumors in blind women as well as an inverse relationship between breast cancer incidence and the degree of visual impairment. Because light inhibits melatonin secretion, the increase in melatonin-circulating levels might be interpreted as proof of the protective role of this hormone on mammary carcinogenesis (5) . A moderate increase in breast cancer risk among women who worked extended periods of rotating night shifts (light exposure during night suppresses melatonin production) has also been described (6) .
Different mechanisms have been proposed to explain how melatonin could reduce the development of mammary tumors; they are indirect neuroendocrine mechanisms such as melatonin regulation of some pituitary and gonadal hormones that control tumor growth (1, 4 -7) and the direct effects of melatonin as an endogenous hydroxyl radical scavenger (8) or as a modulator of the immune response to the presence of a malignant neoplasm (9, 10) . On the other hand, direct anti-estrogenic melatonin actions at the cellular level have been proposed (11, 12) . Studies using MCF-7 human breast cancer cells (ERϩ) 1 (an estrogen-dependent model system, as is the case for more than 60% of primary breast tumors) demonstrate that physiological concentrations of melatonin (1 nM to 1 pM) exert a direct anti-proliferative effect on estrogen-induced proliferation of these cells (11, 12) and reduce their invasiveness, causing a decrease in cell attachment and cell motility, probably by interacting with estrogen-mediated mechanisms (13) . However, the molecular basis of melatonin action remains largely unknown.
In a previous report (14) , we presented evidence that melatonin interferes with estrogen-signaling pathways. We demonstrated that melatonin acts as anti-estrogen by preventing the estrogen-dependent transcriptional activation in MCF-7 cells through destabilization of the E 2 ⅐ER complex from binding to DNA, and we proposed calmodulin (CaM) as a potential candidate for mediating the anti-estrogenic effects of melatonin. Several lines of evidence support this hypothesis; the interaction of this calcium-regulated protein with ER has been known for several years, and a number of CaM antagonists exhibit anti-estrogenic activity and decrease the affinity of ER␣ for its ligand as well as the stability of E 2 ⅐ER binding to DNA (15) . In addition, it has been shown that melatonin binds to calmodulin in a Ca 2ϩ -dependent fashion, resulting in the inhibition of calmodulin (16, 17) .
In the search for differences between ER␣ and the most recently described ER␤, we analyzed the interaction of both receptors with calmodulin, and we demonstrated that ER␣ but not ER␤ directly interacts with calmodulin. Consequently, CaM antagonists are selective modulators of ER␣-mediated transcription (18) . In the present study, we have investigated whether calmodulin could be a link between melatonin and the estrogen-signaling pathway. Our results indicate that melatonin acts as specific inhibitor of ER␣ at physiological doses, and therefore, clinical studies on the possible therapeutic value of melatonin on breast cancer should be considered. Plasmids-The expression vector pcDNA-ER␣ and the recombinant plasmid GST-ER␣-(280 -595) have been previously described (18, 19) . pERE-TK-Luc, pS2-Luc, and pCMX-mER␤ were kindly provided by Dr. V. Giguère from the R. W. Johnson Pharmaceutical Research Institute, Don Mills, Ontario, Canada. pCXN2-hER␤-(1-530), GST-hER␣-(117-595) (20) , and pRL-TK (Promega Corp., Madison, WI) were also used in this work. The plasmid 3x-ERE-TATA-Luc was kindly provided by Dr. S. Safe from the Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX. ⌬coll-73 was kindly provided by Dr. A. Aranda from Instituto de Investigaciones Biomédicas "Alberto Sols" Consejo Superior de Investigaciones Científicas, Madrid, Spain.
EXPERIMENTAL PROCEDURES

Materials
Cell Culture and Transient Transfection Assays-HeLa cells were propagated as previously described (18) . Before transfection, HeLa cells were seeded in 12-well plates and incubated for 12-18 h at 37°C. Then cells were transferred to phenol red-free Dulbecco's modified Eagle's medium containing 0.5% charcoal, dextran-treated fetal calf serum and maintained for 3 days. At 60 -80% confluency, cells were transfected with 0.5 g of estrogen response element (ERE)-driven or AP1-driven reporter plasmids, 0.1 g of ER expression vector, and 50 ng of an internal control Renilla luciferase plasmid, pRL-TK (Promega), using FuGENE 6 transfection reagent from Roche Applied Science following the manufacturer's protocols. After 18 -24 h, medium was renewed, and cells were stimulated for 24 h with different chemicals as indicated.
Luciferase was assayed with the dual luciferase system (Promega). Luciferase activities were normalized to Renilla luciferase activity to correct for differences in transfection efficiency. The results represent the means Ϯ S.D. of three independent experiments performed at least in duplicate. Transactivation experiments were performed with both mouse and human ER␤, and identical trends in ligand behavior were observed in both ER␤s in HeLa cells.
MCF-7 cells were propagated in RPMI 1640 medium containing 25 mM HEPES, NaOH, pH 7.3, and synchronized cells were transfected as above. When indicated, ER␤ expression vector or the empty vector was included in the transfection.
Electrophoretic Mobility Shift Assay-Binding of the E 2 ⅐ER to ERE was performed as previously described (14) . Five to ten microliters of nuclear extracts of transient transfections were mixed with buffer B (20 mM HEPES-KOH, pH 7.9, 10 mM MgCl 2 , 1 mM EDTA, 10% (v/v) glycerol, 100 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM dithiothreitol, 0.5% Nonidet P-40, and protease inhibitors) and incubated with 1 g of poly(dI⅐dC) in a total volume of 40 l. Mixtures were preincubated at 0°C for 15 min followed by incubation with the indicated hormones at 0°C for 10 min.
32 P-Labeled probe (10 fmol containing 3-5 ϫ 10 4 dpm) corresponding to the ERE from Xenopus vitellogenin A 2 gene was added to the reaction and allowed to proceed for 1 h at 0°C followed by 30 min at room temperature. The samples were loaded onto a pre-electrophoresed (10 mA) 5% polyacrylamide gel (acrylamide to bisacrylamide ratio of 40:1) in TBE (45 mM Tris borate, 1 mM EDTA) at 11 mV/cm. Gels were vacuum-dried and exposed at Ϫ80°C to obtain the autoradiography. For specificity assays, a 100-fold excess of unlabeled oligonucleotide was used as competitor before adding the probe to the binding reaction.
Proteolysis Assays-The pcDNA-ER␣ plasmid (1 g) containing fulllength cDNA of the wild-type human ER␣ was used to produce 35 Sradiolabeled ER␣ using 40 l of a coupled transcription-translation system according to the manufacturer's instructions (Promega). The protease digestion was performed essentially as described by
McDonnell et al. (21) . An aliquot (4.5 l) of reticulocyte lysate was incubated for 20 min in the absence or presence of 1 M 17␤-estradiol, 1 nM melatonin, and 1 M W7 as indicated. Equal aliquots of the untreated or the hormone-treated receptor were subsequently incubated with a trypsin solution (Roche Applied Science), giving final enzyme concentration of 25 g/ml. After 10 min of incubation at room temperature, the digestion reaction was terminated by the addition of gel-denaturing buffer and boiling for 5 min. The products of the digestion procedure were separated on a 12% polyacrylamide-SDS gel. After electrophoresis the gel was treated with a 0.5 M sodium salicylate solution for 15 min. The gel was dried under vacuum, and the radiolabeled products were visualized by autoradiography. When indicated, 1 g of goat polyclonal anti-CaM antibodies (SC-1988, Santa Cruz Biotechnology, Inc.) was added before the treatment with hormones.
In Vitro Protein-Protein Interaction Assays-GST fusion proteins were expressed and purified essentially as described by Frangioni and Neel (22) . GST pull-down experiments were performed as previously described by Cavailles et al. (23) . 35 S-Labeled SRC-1a coactivator was synthesized by in vitro transcription-translation (Promega) using pCR-SRC-1a as template. The GST fusion proteins loaded on glutathioneSepharose beads (25 l) were preincubated with 1 M concentrations of ligands (17␤-estradiol, 4-hydroxytamoxifen, or ICI 182,780) or 1 nM melatonin for 30 min at 4°C followed by incubation with 35 S-labeled proteins for 1.5 h at 4°C in a total volume of 150 l of IPAB buffer (20 mM HEPES-KOH, pH 7.9, 5 mM MgCl 2 , 150 mM KCl, 0.02 mg/ml bovine serum albumin, 0.1% (v/v) Triton X-100, 0.1% Nonidet P-40, and protease inhibitors). Beads were washed 4 -5 times with IPAB without bovine serum albumin, collected by centrifugation, and resuspended in 20 l of loading buffer for SDS-PAGE analysis. The gel was vacuum-dried, and the radiolabeled products were visualized by autoradiography.
In Vitro Interaction with Dansyl-CaM-Fluorescence experiments were performed in a PerkinElmer Life Sciences fluorimeter using a 100-l cuvette. 2.5 nmol of dansyl-CaM (Sigma) were dissolved in 100 l of 10 mM MOPS, pH 7.2, 1 mM MgCl 2 , 100 mM KCl, and 1 mM CaCl 2. Emission fluorescent spectra were obtained ( Ex 333 nm) before and after the addition of 1 nM melatonin or the indole derivatives. Equivalent amounts of buffer were added in the controls.
RESULTS
Melatonin Is a Specific Inhibitor of ER␣-mediated Transcription-
We have previously demonstrated that melatonin is able to inhibit estrogen-dependent transcription and proliferation in MCF-7 cells (14) . Because MCF-7 is a carcinoma-derived cell line (ERϩ) that endogenously expresses both ER␣ and ER␤, we further investigated the inhibitory effect of melatonin on E 2 -dependent transactivation mediated by each receptor isoform independently. For this purpose, we transiently transfected HeLa cells with either ER␣ or ER␤ expression vectors along with the ERE-driven reporter plasmids pEREtkLuc (Fig. 1A) , pS2Luc (Fig. 1B) , or 3xERELuc (Fig. 1C) . In all cases 10 nM E 2 stimulated transcription for both ER␣-and ER␤-transfected cells. As expected, the highest E 2 stimulation was obtained using a strong promoter containing three ERE sites (Fig. 1C) . Physiological concentrations of melatonin (1 nM) inhibited ER␣-mediated transactivation by 45-60% depending on the promoter tested. In contrast, ER␤-mediated transcription was not affected (Fig. 1 , B and C) or even potentiated (Fig. 1A ) by this concentration of melatonin. In titration experiments we observed that melatonin inhibited ER␣-mediated transcription in a dose-dependent manner, whereas ER␤ activity was unaffected by the different concentrations of melatonin assayed (Fig. 1D ). These results indicate that melatonin is a selective modulator of ER␣, as we have recently described for CaM antagonists (18) .
An ER␣ Mutant Unable to Bind CaM Is Insensitive to Melatonin-In a previous report we demonstrated that residues
Lys-302 and Lys-303 of hER␣ are essential for CaM binding. Although the wild-type ER␣ normally binds to CaM, substitution of lysines 302 and 303 by glycine abolished the interaction of ER␣ (K302G,K303G) with CaM (18). Transcriptional activation studies further demonstrated that these two critical resi-dues for ER␣ binding to CaM are not essential for ER␣ transcriptional activation. Thus, when HeLa cells were transiently transfected with wild-type ER␣ and compared with those transfected with ER␣ (K302G,K303G), both showed similar levels of basal and E 2 -induced transcriptional activation (18) . However, ER␣ transactivation was 80% inhibited by 10 Ϫ6 M W7, whereas transcription mediated by ER␣ (K302G,K303G) was completely insensitive to this calmodulin antagonist. If melatonin acts as a calmodulin antagonist on ER␣-mediated transcription, we could predict no inhibitory effect of the pineal hormone on ER␣ (K302G,K303G)-mediated transactivation. Indeed, when HeLa cells were transiently transfected with ER␣ (K302G,K303G) along with the ERE-driven reporter plasmid 3xERELuc (Fig. 1E ) we observed that ER␣ (K302G, K303G) transcription was unaffected by the different concentrations of melatonin assayed.
The Sensitivity of MCF7 Cells to Melatonin Depends on the ER␣/ER␤ Ratio-In MCF7 cells increasing concentrations of melatonin resulted in the progressive inhibition of the E 2 -dependent transcription, reaching nearly 100% of inhibition at pharmacological concentrations of melatonin ( Fig. 2A) . The IC 50 was obtained at 1.26 ϫ 10 Ϫ11 M as determined with GraphPad Prism.
We next analyzed whether the sensitivity of MCF7 cells to inhibition by melatonin was associated with the high ER␣/ER␤ ratio present in these cells, as we have previously reported for CaM antagonists (18) . To test this hypothesis, MCF7 cells were transfected with the 3xERELuc reporter plasmid in the absence or presence of an ER␤ expression vector. We then determined whether ER␤ overexpression affects the sensitivity of these cells to melatonin and compared its effect to those of the CaM antagonists W7 and calmidazolium. As expected, both melatonin and CaM antagonists inhibited E 2 -dependent transcriptional activation in MCF7 cells (Fig. 2B) . Interestingly, the inhibitory effects of both melatonin and CaM antagonists were abolished by ER␤ overexpression (Fig. 2B) . These results imply that the sensitivity to melatonin of E 2 -induced transcription in MCF7 cells depends on the presence of ER␣. Inhibition by melatonin correlates with a high ER␣/ER␤ ratio, whereas an increased expression of ER␤ impairs the effect of the hormone.
Melatonin Inhibits E 2 ⅐ER␣-mediated Transcription in AP1-containing Promoters-We have previously demonstrated that FIG. 1. Differential effect of melatonin on the transactivation properties of ER␣ and ER␤. HeLa cells were transfected with 0.1 g of ER␣ or ER␤ expression vectors, 50 ng of the internal control plasmid pRL-TK, and 0.5 g of the following ERE-driven reporter plasmids pEREtkLuc (A), pS2Luc (B) or 3xERELuc (C). After 18 -24 h, medium was renewed, and cells were stimulated for 24 h with 10 nM E 2 and 1 nM melatonin (Mel) as indicated. Luciferase activities were normalized to the Renilla luciferase activities. The data are reported as fold induction relative to untreated cells, which were arbitrarily assigned as 1. The bars represent the mean Ϯ S.D. of three independent experiments performed in duplicate. The asterisk indicates a statistical significant difference (Student's t test), p Ͻ 0.05, between the groups. D, dose response to melatonin of E 2 -induced ER␣ (E) or ER␤ (q) transactivation. HeLa cells were processed as above and treated with 10 nM E 2 and the indicated concentrations of melatonin. E 2 -dependent luciferase activity is expressed as the percentage of E 2 stimulation. The bars represent the means Ϯ S.D. of three independent experiments run in duplicate. These results were significantly different from E 2 -stimulated transcription: *, p Ͻ 0.05; **, p Ͻ 0.01. E, dose response to Mel of E 2 -induced ER␣ (E) or ER␣ (K302G,K303G) (q) transactivation. HeLa cells were transfected with 0.5 g of 3xERELuc reporter plasmid, 50 ng of the internal control plasmid pRL-TK, and 0.1 g of either ER␣ or ER␣ (K302G,K303G) expression vectors, and cells were treated with 10 nM E 2 and the indicated concentrations of melatonin. These results are significantly different than E 2 -stimulated transcription: *, p Ͻ 0.05; **, p Ͻ 0.01.
CaM is a regulator of ER␣-mediated transcription in both EREand AP1-containing promoters since transcription mediated by both complexes is sensitive to CaM antagonists (18) . Therefore, we decided to test the ability of melatonin to inhibit transcription on ER␣/AP1 pathways. For that purpose, HeLa cells were transfected with either ER␣ or ER␤ along with the reporter plasmid ⌬coll-73-Luc (containing an AP1 binding site). Even though E 2 ⅐ER␣-mediated AP1 activation in HeLa cells and other cell lines have been described (24, 25) , we and other authors found it necessary to prime the cells with EGF to observe this effect. EGF stabilizes the levels of c-Jun and c-Fos family proteins, allowing a synergistic effect between these factors and ER␣ on AP1 transcription (26, 27) . We found that AP1 activity was increased by EGF in cells expressing either ER␣ or ER␤ (Fig. 3) . E 2 significantly potentiated AP1 activity in ER␣-transfected cells but diminished AP1 activity in ER␤-transfected cells. These results agree with previous reports (26, 27) indicating that EGF synergizes with E 2 . Very importantly, the synergistic effect of EGF and E 2 in cells expressing ER␣ was sensitive to melatonin, whereas no effect was observed in cells expressing ER␤. Both the activation by E 2 and the inhibition by melatonin were statistically significant. We can infer from these experiments that melatonin, as other CaM antagonists, regulates ER␣-mediated transcription not only in EREdependent pathways but also in AP1 pathways.
Melatonin but Not Other Indole Derivatives Interact with CaM-We have previously demonstrated that melatonin blocks the binding of the E 2 ⅐ER complex to ERE in vitro and that this effect is dose-dependent, saturable, and specific, since different methoxy-and hydroxyindoles have no effect on binding to DNA (14) . Therefore, we expected that other indole derivatives would have no effect on E 2 ⅐ER␣-mediated transcription. To analyze this possibility we carried out transient transfections in MCF-7 cells using 3xERE-Luc as reporter plasmid. As shown in Fig. 4B , melatonin effectively inhibited (60%) E 2 -induced transactivation, whereas treatment with other indole metabolites resulted in no significant decrease on the E 2-mediated transcription, indicating that the inhibitory effect of melatonin on estrogen response is specific.
To further investigate the basis for the specific inhibition exhibited by melatonin, we examined the ability of the indole derivatives to bind to dansyl-CaM. Changes on emission fluorescence intensity of dansyl-CaM reflect conformational/structural changes, suggesting interaction with CaM. As observed in Fig. 4C , melatonin specifically decreased the fluorescence of dansyl-CaM, whereas the other indoles tested did not modify the fluorescence of dansyl-CaM, indicating that only melatonin is able to interact with this protein. We hypothesize that melatonin acts as a CaM antagonist, interfering with the ER␣-CaM complex and that this is the underlying basis by which melatonin specifically inhibits ER␣-mediated transcription.
Melatonin Induces Conformational Changes on ER␣ Structure via CaM-Conformational changes on ER␣ structure can be shown by using a protease digestion assay as previously described by McDonnell et al. (21) . Also, W7 induces CaM to form a globular structure (29) . We have determined the effects of melatonin and W7 on ER␣ structure on the basis of the differential susceptibility of the receptor to proteolysis by trypsin. 35 S-Labeled ER␣ was synthesized in vitro and preincubated with vehicle, E 2 , melatonin, W7, or combinations of these compounds. The resulting complexes were then subjected to limited digestion with trypsin, and the products were resolved by SDS-PAGE (Fig. 5) . ER␣ was highly sensitive to trypsin degradation in the absence of ligand (Fig. 5, lane 2) , whereas in the presence of E 2 , a trypsin-resistant 32-kDa fragment was observed (Fig. 5, lane 4) , in agreement with results previously published (21) . Incubation of the labeled receptor in the presence of E 2 plus either melatonin (Fig. 5, lane 6) or W7 (Fig. 5,  lane 8) yielded a distinct digestion patron as compared with E 2 alone. Under these conditions, ER␣ becomes highly sensitive to protease digestion. Therefore, treatment with melatonin or CaM antagonists abolished the protective effect of E 2 on limited trypsin digestion. Interestingly, the effects of melatonin (Fig. 5, lane 5) and W7 (Fig. 5, lane 7) were reverted in the presence of anti-CaM antibodies. Taken together, our data indicate that melatonin, similar to W7 through the interaction with CaM, induce conformational changes on ER␣ that also affect the stability of ER␣ against proteolysis.
ER␣ Stability Is Not Altered by Melatonin-It has been reported that the inhibition of the interaction between CaM and
FIG. 2. The sensitivity of MCF7 cells to melatonin and CaM antagonists is abolished by ER␤ overexpression.
A, dose response to melatonin of E 2 -dependent transactivation in MCF-7 cells. Transfections were performed by using 0.5 g of 3xERELuc reporter plasmid, and after 18 -24 h, cells were stimulated for 24 h with either 10 nM E 2 alone or 10 nM E 2 plus the indicated concentrations of melatonin. An IC 50 value of 1.26 ϫ 10 Ϫ11 M was generated by non-linear regression analysis using GraphPad Prism, version 3.02 for windows (GraphPad Software, Inc., San Diego, CA). B, MCF-7 cells were transfected with 0.5 g of the reporter plasmid 3xERELuc, 50 ng of pRL-TK plasmid, and when indicated, with 0.4 g of ER␤ expression vector (right set of data). The total amount of DNA was held constant to 0.95 g per well by the addition of empty expression vector. After transfection, cells were treated for 24 h with 10 nM E 2 , 1 nM melatonin (Mel), 0.1 M W7, or 0.1 M calmidazolium (Calm) as indicated. Luciferase activities were normalized to the Renilla luciferase activities. The data are reported as -fold induction relative to untreated cells, which were arbitrarily assigned as 1. The bars represent the means Ϯ S.D. of three independent experiments performed in duplicate. These results are significantly different than E 2 -stimulated transcription: *, p Ͻ 0.05; **, p Ͻ 0.01.
ER reduces the total cellular content of estrogen receptor (28) . Thus, treatment of MCF7 cells with calmodulin antagonists such as trifluoperazine (TFP) or CGS9343B reduced the number of estrogen receptors in the cells (30) . We have addressed whether the inhibition of ER␣ activity by melatonin in MCF7 cells could be due to the modulation of the stability and the state level of estrogen receptors. For this purpose, MCF7 cells were treated for 24 h with either vehicle, E 2, melatonin, TFP, or combinations, and ER protein levels were determined by Western blot. As shown in Fig. 6 , E 2 (fourth lane) and TFP ( fifth   FIG. 3 . Effect of melatonin on E 2 -dependent transactivation at an AP1 element. HeLa cells were transfected with either 0.1 g of the ER␣ or ER␤ expression vectors, 50 ng of internal control plasmid pRL-TK, and 0.5 g of the AP1-containing reporter plasmid (⌬coll-73-Luc). Cultures were stimulated for 48 h with 1 g/ml EGF, 100 nM E 2 , and 100 nM melatonin (Mel) as indicated. The data are reported as -fold induction relative to untreated cells, which were arbitrarily assigned as 1. The bars represent the means Ϯ S.D. of three independent experiments run in duplicate. *, significantly different relative to EGF treatment (p Ͻ 0.05). #, significant relative to EGF plus E 2 treatment (p Ͻ 0.05).
FIG. 4. Effect of different hydroxy-and methoxyindoles on ER␣-mediated transcription and interaction with dansyl-CaM.
A, schematic diagram of the indole derivatives implicated in the metabolism of melatonin. B, HeLa cells were transfected with 0.1 g of the ER␣ expression vector, 50 ng of internal control plasmid pRL-TK, and 0.5 g of 3xERELuc as ERE-driven reporter plasmid. After 18 -24 h, medium was renewed, and cells were stimulated for 24 h with 10 nM E 2 or 10 nM E 2 plus either 1 nM melatonin (Mel), 6-hydroxymelatonin (HM), 5-methoxytryptamine (MT), serotonin (S), 5-hydroxytryptophan (HT), or 5-hydroxyindole acetate (HIA) as indicated. Luciferase activities were normalized to the Renilla luciferase activities. The data are reported as fold induction relative to untreated cells, which were arbitrarily assigned as 1. The bars represent the means Ϯ S.D. of three independent experiments run in duplicate. Significant difference from E 2 -stimulated transcription: **, p Ͻ 0.01. C, ability of the different indoles to bind dansyl-CaM. Emission fluorescence spectra of 25 M dansyl-CaM in 10 mM MOPS (pH 7.2), 1 mM MgCl 2 , 100 mM KCl, and 1 mM CaCl 2 were determined, and this intensity was arbitrarily assigned the value 1. 1 nM melatonin, 6-hydroxymelatonin, 5-methoxytryptamine, serotonin, 5-hydroxytryptophan, or 5-hydroxyindole acetate was added, and fluorescence was determined after the addition of each compound. The bars represent the means Ϯ S.D. of two independent experiments performed in duplicate. **, significant relative to untreated cells; p Ͻ 0.01. lane) significantly reduced ER␣ content in MCF7 cells, in agreement with previous data (30) . Strikingly, treatment with 100 nM melatonin does not alter the amount of ER␣ in the cells (Fig. 6, second lane) , indicating that inhibition of ER␣-mediated transcription by melatonin is not due to a reduction in ER protein levels. Importantly, neither TFP nor melatonin affected ER␤ levels, suggesting that the interaction with CaM is important to trigger degradation since ER␣ but not ER␤ interacts with calmodulin.
Effect of Melatonin on Coactivator Binding Properties of ER␣-ER␣ is a transcriptional factor allosterically regulated
by ligand, which promotes gene transcription by recruiting coactivator proteins in a ligand-dependent manner (31) . Because melatonin actions involve alterations on ER structure that could interfere with the association of factors required for ER activity, we analyzed whether melatonin affects the binding of the coactivator SRC-1a to ER␣. GST pull-down experiments were performed by using 35 S-labeled SRC-1a and GST-ER␣-(117-595) purified and immobilized on GSH-Sepharose as an affinity reagent (Fig. 7, A and B) . As expected, the binding of SRC-1a to ER␣ was stimulated 3-fold in the presence of E 2 , and the presence of the estrogenic antagonists 4-hydroxytamoxifen (OHT) and ICI blocked this association to ER␣ (28) . By contrast, the E 2 -dependent interaction of SRC-1a with ER␣ was unaffected by melatonin. Both melatonin and anti-estrogens failed to induce by themselves SRC-1a association to ER␣. These results strongly suggest that the mechanism of melatonin action differs from those of anti-estrogens such as OHT or ICI, which exert inhibitory effects on ER activity by impairing coactivator recruitment.
Because melatonin induces conformational changes on ER␣ structure and this fact seems to have no consequences on the binding of coactivators, we postulate that CaM and coactivator binding to ER are independent phenomena. To check this, we determined whether forms of ER␣ unbound to CaM retain the ability to interact with coactivators. This was accomplished in another set of GST pull-down experiments using 35 S-labeled SRC-1a and the hybrid protein GST-ER␣-(280 -595), which is unable to bind CaM (18) immobilized on GST-Sepharose as affinity reagent (Fig. 7, C and D) . Under these conditions the binding of SRC-1a to GST-ER␣-(280 -595) was induced by E 2 , and once again the presence of melatonin had no effect on this interaction, whereas the presence of OHT impaired SRC-1a association. These results indicate that the binding of CaM to ER␣ is not a prerequisite for the recruitment of coactivators and that these are two independent mechanisms for the regulation of ER␣ activity.
Melatonin Selectively Prevents the Binding of E 2 ⅐ER␣ Complex to ERE in Vitro-We have investigated whether the selective inhibition of ER␣-mediated transcription by melatonin is exerted at the level of DNA binding. To accomplish this, we conducted electrophoretic mobility shift assays using nuclear extracts from HeLa cells transfected with ER␣ or ER␤ to determine the effect of melatonin on the E 2 -dependent binding of each ER isoform to ERE. ER␣ binding to ERE was increased 3-fold in the presence of 10 nM E 2 (Fig. 8, lane 2) . This binding was 90% inhibited by the addition of 1 nM melatonin (Fig. 8,  lane 3) . In a similar way the binding of ER␤ to ERE was also increased 2.5-fold in the presence of E 2 (Fig. 8, lane 5) , but contrary to ER␣ the addition of melatonin stimulated the binding of ER␤ to DNA (Fig. 8, lane 6) . The specificity of the retarded band was demonstrated by competition with a 100-fold excess of unlabeled ERE (Fig. 8, lane 7) .
Taken together, our results indicate that melatonin induces conformational changes in CaM that selectively prevent ER␣-dependent transcription by destabilizing the binding of E 2 ⅐ER␣⅐CaM complex to DNA either by modulating ER stability at protein level or by impairing coactivator binding to the receptor.
DISCUSSION
Melatonin is an indole hormone secreted by the pineal gland only during the night or, more exactly, in darkness. One of the proposed properties of melatonin is its role as an oncostatic agent on hormone-dependent tumors. It has also been described that melatonin exerts antiproliferative effects on MCF7 cells, which has become a useful model to study the antiestrogenic effect of the pineal hormone (11, (32) (33) (34) (35) . In synchronized MCF7 cells, both estrogen-dependent transcription and proliferation are inhibited by co-treatment with melatonin. It has been shown that melatonin binds to calmodulin in a Ca 2ϩ -dependent fashion, resulting in inhibition of calmodulin (16, 17) . We have proposed (14) that calmodulin might be a potential candidate to mediate the anti-estrogenic effects of melatonin. In this regard, we have recently demonstrated that ER␣ but not ER␤ interacts with calmodulin, and mutations in the postulated (36) ER␣ calmodulin binding site abolish this inter- action (18) . The mutant receptor is otherwise fully functional promoting E 2 -dependent transcription. As a consequence of the interaction of the receptor with this calcium ligand protein, CaM antagonists act as specific inhibitors of ER␣ in a dose-dependent manner but show no inhibitory effect on ER␤-mediated transcription both in ERE-and AP1-driven promoters (18) . Considering the observations mentioned above, we addressed the question of whether the inhibitory effects observed in MCF7 cells treated with melatonin were exerted via CaM. For this purpose we studied the effect of melatonin on E 2 -dependent transactivation mediated by each receptor in transfected HeLa cells. We found that similarly to CaM antagonists, melatonin inhibits E 2 ⅐ER␣-induced transcription at several ERE-driven promoters, whereas ER␤ activation is not inhibited (or even enhanced at certain promoters) by treatment with the hormone. Importantly, the ER␣ (K302G,K303G) mutant, which does not interact with CaM, is not inhibited by melatonin and behaves in a similar fashion to that of the ER␤ receptor. This result strongly suggests that the effect of the hormone is directly exerted through the calmodulin bound to ER␣ and not through indirect pathways. All the data mentioned above indicate that melatonin is a selective modulator of estrogen receptors. This observation is extremely important since more than 60% of breast cancers show overexpression of ER␣, and the ratio ER␣/ER␤ increases during breast and ovarian tumor progression (37) . Therefore, melatonin, as we have previously suggested for CaM antagonists, might have the potential to act as an ER␣ inhibitor with antitumor effects on advanced breast, ovarian, and colon cancer.
We have attempted to determine if the inhibitory effects observed in MCF7 cells treated with melatonin are associated with the high ER␣/ER␤ ratio present in these cells as we have reported for CaM antagonists (18) . Indeed, in MCF7 cells expressing ectopic ER␤, the inhibitory effects of melatonin and CaM antagonists were abolished. These results imply that the sensitivity to melatonin correlates with a high ER␣/ER␤ ratio.
Because we had previously found that CaM antagonists also inhibit ER␣-dependent AP1 transcriptional activity (18) we tested the ability of melatonin to inhibit ER␣-mediated transcription in AP1-driven promoters. As expected, melatonin significantly inhibited AP1/ER␣ activation by E 2 . Therefore, melatonin also acts as a regulator of the ER␣-CaM/AP1 pathway. CaM inhibitors and tamoxifen have been reported to show synergistic inhibitory effects (33) . Thus, we propose that melatonin could be a valuable tool to block the mitogenic activity of ER␣ in both anti-estrogen-responsive and anti-estrogen-resistant breast cancer cells.
We have previously reported that melatonin blocks the binding of E 2 ⅐ER complex to ERE in vitro, but other methoxy-and hydroxyindoles were not effective in doing so. Therefore, we predicted that these compounds would have neither effect on E 2 -dependent transactivation nor ability to bind dansyl-CaM. The effect of melatonin is indeed, specific, since none of the compounds tested inhibited E 2 -dependent transcription or modified the fluorescence of dansyl-CaM.
The next question we addressed was whether melatonin has any effect on the stability of ER␣, as it has been described for other calmodulin antagonists (30) . MCF7 cells treated with CaM antagonist TFP show a 50% reduction in the ER levels, and nearly all the receptor disappeared when CGS9343B was used. These compounds did not significantly modify the level of ER mRNA. It has been, therefore, proposed that calmodulin stabilizes the receptor against proteolysis (30) . The same authors suggested that the inhibitory effect of W7 on ER␣-mediated transcription that we have previously reported (18) might be due to the reduction in ER-protein levels induced by CaM antagonists (38, 39) . Treatment with melatonin did not alter the amount of ER␣ present in MCF7 cells, whereas cells treated with TFP did show a reduction in the ER levels similar to that previously reported (37) . Therefore, the possibility that melatonin inhibits ER␣ transcription as a consequence of degradation of the receptor can be excluded. Notably, the levels of ER␤ remain unaffected in all the conditions assayed.
We next investigated melatonin to determine if it might interfere with the association of factors required for ER␣ activity. Anti-estrogens induce a conformational change in the receptor different to that of E 2 in such way that corepressors and not coactivators bind to the receptor in the presence of the tamoxifen (40) . We, therefore, considered the possibility that melatonin might have a similar effect and that the conformational change induced by melatonin on CaM might imply another change on ER␣ structure in such way that coactivator association to the receptor would be impaired. We have analyzed the binding of the coactivator SRC-1a to ER␣. We found that, as previously reported (41, 42) , the binding of SRC-1a to ER␣ was stimulated by E 2 , whereas the presence of the estrogenic antagonists OHT and ICI blocked this association. On the other hand, E 2 -dependent interaction of SRC-1a with ER␣ was unaffected by melatonin, indicating that this is not the mechanism by which melatonin exerts its inhibitory effect on ER␣-mediated transcription. We have also shown that CaM and coactivator binding to ER␣ are independent phenomena, since a GST fusion with a truncated ER␣ unable to interact with CaM recruits SRC-1a, and this association is enhanced by estradiol and inhibited by OHT and ICI. In other words, our results strongly suggest that CaM binding to ER␣ is not a necessary event for coactivator recruitment. This idea is further supported by the fact that the mutant ER␣ (K302G,K303G), which does not bind CaM, mediates transcription in a similar way to that of wild-type ER␣, although treatment with melatonin does not inhibit its actions. How then does melatonin inhibit transcription? We have investigated whether the differential action of melatonin on E 2 -dependent transcription by ER␣ and ER␤ was exerted on binding of ER to DNA. We performed electrophoretic mobility shift assays using nuclear extracts from HeLa cells expressing either ER␣ or ER␤ to determine the effect of melatonin on the E 2 -dependent binding of each receptor isoform to ERE. The binding of ER␣ to DNA was increased in the presence of estradiol and inhibited by melatonin. On the other hand, melatonin further enhanced the binding of ER␤ to DNA, which might explain why at certain promoters co-treatment with E 2 and melatonin enhanced ER␤ transcriptional activity.
As mentioned above, the ratio ER␤/ER␣, which is high in normal tissues, decreases during breast and ovarian tumor progression (43) and in both male and female malignant transformation of the colon (44, 45) . Notably a large scale study conducted on long time night-shift workers indicates that those working night shifts at least three nights per month for 15 years or longer have a moderate but significant increase in the risk of developing breast and colon cancer (6, 46) . Because the levels of ER␤ are reduced during tumor progression in most colon cancers, melatonin might be important for prevention of the breast and colon malignancies acting through ER␣. Our results favor the concept that melatonin and CaM antagonists could be of therapeutic importance in tumors with high ER␣/ ER␤ ratio, that is, in advanced tumors. In addition, CaM antagonists alone or in combination with anti-estrogens have been reported to decrease the viability and induce apoptosis of breast cancer cells (47) (48) (49) . Melatonin decreased toxicity and increased efficacy of cancer chemotherapy in metastatic patients with poor clinical status (50) .
In summary, the reported data and the results presented in this work strongly suggest that melatonin or melatonin derivatives with no toxicity and higher efficacy than the pineal hormone may have the potential to act as inhibitory agents of ER␣ with anti-tumor effects on advanced breast, ovarian, and colon tumors. Therefore, clinical studies on the possible therapeutic value of melatonin on these cancers should be performed in the future.
